3, 4-Methylenedioxymethamphetamine (MDMA/ 'Ecstasy') Ingestion and Acute Liver Failure

被引：0
|
作者：
Mohamed, Zubair U. [1 ]
Willars, Chris [1 ]
Auzinger, Georg [1 ]
Heneghan, Michael [1 ]
Heaton, Nigel [1 ]
Wendon, Julia [1 ]
Bernal, William [1 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England
来源：
LIVER TRANSPLANTATION | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
O-117
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [31] Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy)
    Movassaghi, Shabnam
    Sharifi, Zahra Nadia
    Mohammadzadeh, Farzaneh
    Soleimani, Mansooreh
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2013, 16 (08) : 922 - 927
  • [32] The Acute Psychobiological Impacts of Illicit 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') Consumption in Recreational Environments
    Morefield, K. M.
    Keane, M.
    Felgate, P.
    White, J. M.
    Irvine, R. J.
    NEUROPSYCHOBIOLOGY, 2009, 60 (3-4) : 216 - 216
  • [33] Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
    Wunderli, Michael D.
    Vonmoos, Matthias
    Treichler, Lorena
    Zeller, Carmen
    Dziobek, Isabel
    Kraemer, Thomas
    Baumgartner, Markus R.
    Seifritz, Erich
    Quednow, Boris B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (04): : 333 - 344
  • [34] Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users:: a controlled study
    McCann, UD
    Mertl, M
    Eligulashvili, V
    Ricaurte, GA
    PSYCHOPHARMACOLOGY, 1999, 143 (04) : 417 - 425
  • [35] Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users
    McCann, Una D.
    Edwards, Robert R.
    Smith, Michael T.
    Kelley, Kristen
    Wilson, Michael
    Sgambati, Francis
    Ricaurte, George
    PSYCHOPHARMACOLOGY, 2011, 217 (04) : 475 - 484
  • [36] A new cause of valvular heart disease: 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy')
    Montastruc, F.
    Montastruc, G.
    Vigreux, P.
    Bruneval, P.
    Guilbeau-Frocher, C.
    Cron, C.
    Bagheri, H.
    Delisle, B.
    Lapeyre-Mestre, M.
    Pathak, A.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 10 - 10
  • [37] Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
    Montastruc, Francois
    Montastruc, Guillaume
    Vigreux, Philippe
    Bruneval, Patrick
    Guilbeau-Frugier, Celine
    Cron, Christophe
    Bagheri, Haleh
    Delisle, Bernadette
    Lapeyre-Mestre, Maryse
    Pathak, Atul
    Montastruc, Jean-Louis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (03) : 547 - 548
  • [38] REVIEW OF THE PHARMACOLOGY AND CLINICAL-PHARMACOLOGY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA OR ECSTASY)
    GREEN, AR
    CROSS, AJ
    GOODWIN, GM
    PSYCHOPHARMACOLOGY, 1995, 119 (03) : 247 - 260
  • [39] Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study
    U. D. McCann
    Melissa Mertl
    Victoria Eligulashvili
    George A. Ricaurte
    Psychopharmacology, 1999, 143 : 417 - 425
  • [40] Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram
    Matthias E Liechti
    Christine Baumann
    Alex Gamma
    Franz X Vollenweider
    Neuropsychopharmacology, 2000, 22 : 513 - 521
12345